- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00547586
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
August 8, 2020 updated by: Bausch Health Americas, Inc.
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid- Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
122
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
-
-
Arizona
-
Litchfield Park, Arizona, United States, 85340
-
Tucson, Arizona, United States, 85741
-
Tucson, Arizona, United States, 85710
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71901
-
Hot Springs, Arkansas, United States, 71903
-
-
California
-
Garden Grove, California, United States, 92843
-
Long Beach, California, United States, 90813
-
Los Angeles, California, United States, 90048
-
Murrieta, California, United States, 30060
-
San Diego, California, United States, 92121
-
-
Florida
-
Chiefland, Florida, United States, 32626
-
Jacksonville, Florida, United States, 32216
-
Jupiter, Florida, United States, 33458
-
Largo, Florida, United States, 33770
-
Naples, Florida, United States, 34104
-
Ocala, Florida, United States, 34471
-
Ormond Beach, Florida, United States, 32174
-
Spring Hill, Florida, United States, 34609
-
-
Illinois
-
Chicago, Illinois, United States, 60610
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
-
-
Louisiana
-
Sunset, Louisiana, United States, 70584
-
-
Maryland
-
Elkridge, Maryland, United States, 21075
-
-
Massachusetts
-
Brockton, Massachusetts, United States, 2301
-
-
Michigan
-
Cadillac, Michigan, United States, 49601
-
Traverse City, Michigan, United States, 49684
-
-
Mississippi
-
Biloxi, Mississippi, United States, 39531
-
Ocean Springs, Mississippi, United States, 39564
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
-
Winston-Salem, North Carolina, United States, 27103
-
-
Ohio
-
Dayton, Ohio, United States, 45439
-
Toledo, Ohio, United States, 43623
-
-
Oregon
-
Medford, Oregon, United States, 97504
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
-
-
Texas
-
Beaumont, Texas, United States, 77701
-
Colleyville, Texas, United States, 76034
-
Dallas, Texas, United States, 75230
-
San Antonio, Texas, United States, 78229
-
-
Virginia
-
Alexandria, Virginia, United States, 22304
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult outpatients with opioid-induced bowel dysfunction and chronic pain, which is not due to malignant cancer.
- Taking oral, transdermal, intravenous, or subcutaneous opioids.
- Willingness to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives.
Exclusion Criteria:
- History of chronic constipation before the initiation of opioid therapy.
- Other GI disorders known to affect bowel transit.
- Women who are pregnant, breast-feeding, or plan to become pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
placebo
|
Experimental: 300 mg
|
Oral
|
Experimental: 600 mg
|
Oral
|
Experimental: 150 mg
|
Oral
|
Experimental: 450 mg
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants With a Spontaneous Bowel Movement (SBM) Within 1, 2, 3, 4, and 6 Hours of Treatment
Time Frame: 6 hours
|
6 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
October 19, 2007
First Submitted That Met QC Criteria
October 19, 2007
First Posted (Estimate)
October 22, 2007
Study Record Updates
Last Update Posted (Actual)
August 20, 2020
Last Update Submitted That Met QC Criteria
August 8, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3200A3-2201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Chulalongkorn UniversityNot yet recruitingFunctional ConstipationThailand
-
Min-Tze LIONGDeyang People's HospitalRecruiting
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional ConstipationUnited States, Bulgaria, United Kingdom, Croatia, Germany, Hungary
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States